Summit Therapeutics, Inc. (SMMT)
13.04
-1.26
(-8.78%)
USD |
NASDAQ |
Jun 10, 16:00
13.06
+0.02
(+0.19%)
After-Hours: 16:49
Summit Therapeutics Enterprise Value : 10.51B for June 9, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| June 09, 2026 | 10.51B |
| June 08, 2026 | 10.37B |
| June 05, 2026 | 10.88B |
| June 04, 2026 | 10.94B |
| June 03, 2026 | 11.12B |
| June 02, 2026 | 10.95B |
| June 01, 2026 | 11.61B |
| May 29, 2026 | 13.03B |
| May 28, 2026 | 12.93B |
| May 27, 2026 | 12.90B |
| May 26, 2026 | 12.62B |
| May 22, 2026 | 12.32B |
| May 21, 2026 | 12.98B |
| May 20, 2026 | 13.31B |
| May 19, 2026 | 11.72B |
| May 18, 2026 | 11.86B |
| May 15, 2026 | 12.51B |
| May 14, 2026 | 13.50B |
| May 13, 2026 | 14.01B |
| May 12, 2026 | 14.13B |
| May 11, 2026 | 13.90B |
| May 08, 2026 | 13.45B |
| May 07, 2026 | 12.73B |
| May 06, 2026 | 13.28B |
| May 05, 2026 | 13.03B |
| Date | Value |
|---|---|
| May 04, 2026 | 12.60B |
| May 01, 2026 | 11.93B |
| April 30, 2026 | 16.08B |
| April 29, 2026 | 15.59B |
| April 28, 2026 | 15.92B |
| April 27, 2026 | 16.59B |
| April 24, 2026 | 16.56B |
| April 23, 2026 | 16.70B |
| April 22, 2026 | 18.50B |
| April 21, 2026 | 19.89B |
| April 20, 2026 | 18.92B |
| April 17, 2026 | 18.94B |
| April 16, 2026 | 18.37B |
| April 15, 2026 | 15.81B |
| April 14, 2026 | 15.60B |
| April 13, 2026 | 14.96B |
| April 10, 2026 | 14.69B |
| April 09, 2026 | 14.41B |
| April 08, 2026 | 14.02B |
| April 07, 2026 | 14.34B |
| April 06, 2026 | 13.92B |
| April 02, 2026 | 14.46B |
| April 01, 2026 | 14.10B |
| March 31, 2026 | 14.13B |
| March 30, 2026 | 12.47B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Revolution Medicines, Inc. | 28.47B |
| Denali Therapeutics, Inc. | 2.351B |
| NovelStem International Corp. | 1.979M |
| Brainstorm Cell Therapeutics, Inc. | 9.859M |
| Kezar Life Sciences, Inc. | -11.12M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -189.42M |
| Total Expenses (Quarterly) | 189.42M |
| EPS Diluted (Quarterly) | -0.2443 |
| Earnings Yield | -12.30% |
| Normalized Earnings Yield | -12.30 |